RetinAI announces multi-year software license and services agreement for RetinAI Discovery® UNITY platform
Bern, Switzerland, April 30, 2022
RetinAI Medical AG (“RetinAI”) announces a multi-year license and services agreement with Novartis AG (“Novartis”) for its Discovery® UNITY platform. Discovery UNITY is RetinAI’s top of the line enterprise-wide solution to aggregate imaging data for global organizations, including data from clinical and real-world evidence studies, with AI that can be applied to improve understanding of patient populations and outcomes at scale.
Through the RetinAI Discovery UNITY platform, customers can apply RetinAI’s most advanced tools to support their research and clinical development pipeline in Ophthalmology, accelerating data analytics and research workflows. Companies like Novartis can use this platform to characterize diseases and patient outcomes based on at-scale data organization, data aggregation and applied AI from regulatory-approved and AI research models for diseases in Ophthalmology. RetinAI’s AI models include applications in Age-related Macular Degeneration (including Geographic Atrophy), Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion and Glaucoma.
“We are very excited to expand our existing relationship with Novartis and see them as an important partner in implementing the future of digital precision medicine,” said Dr. Carlos Ciller, CEO of RetinAI. “We believe RetinAI’s UNITY platform will redefine how data analysis is performed in drug development, creating opportunities for more cost-effective, target-based research in discovery and clinical trial design.”
RetinAI’s UNITY platform leverages clinical and evidence from the real world to improve understanding of treatment outcomes. The AI capabilities integrated in RetinAI’s Discovery UNITY platform allows for quick data processing at-scale with expert-level analysis and insights extraction. These tools can enhance understanding of eye diseases and help better define patient populations around the globe.
RetinAI Medical AG (RetinAI), founded in early 2017, is a Swiss company developing software solutions to accelerate clinics, research and pharmaceutical workflows globally using advanced machine learning and computer vision. The company builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals and companies to make the right decisions sooner. RetinAI has developed solutions for data management and analytics for research, clinical studies, patient management and RWE analysis. RetinAI's international team combines clinical, technical, and scientific knowledge to foster innovation for preventive solutions to address severe diseases affecting the eye. www.retinai.com